Health Ministry Proposes Defining Antimicrobials As New Drug Class

Published : Nov 19, 2026, 12:00 PM IST
Representative Image (Photo/ANI)

Synopsis

The Union Health Ministry aims to reclassify antimicrobials as new drugs under 2019 rules. This move seeks to enforce stricter manufacturing oversight, improve safety efficacy, and address global concerns regarding antimicrobial resistance.

Health Ministry Proposes Defining Antimicrobials As New Drug Class

The Union Ministry of Health and Family Welfare has proposed an amendment to the New Drugs and Clinical Trials Rules, 2019, to include 'antimicrobials' in the definition of 'New Drug' under Rule 2(1)(w)(v). The proposed amendment has been introduced through a draft Gazette Notification G.S.R. 983 (E) dated November 6.

Antimicrobial resistance (AMR) is a major global public health concern and a priority requiring coordinated action. The G20 New Delhi Leaders’ Declaration also underscored the need to address antimicrobial resistance through a One Health approach. The proposed amendment has been initiated in view of concerns regarding the grant of manufacturing licences for antimicrobial products without adequate regulatory scrutiny, including the requirement for studies such as bioavailability/bioequivalence and stability studies. The absence of such assessments may affect the quality, safety and efficacy of antimicrobial products. Substandard or ineffective antimicrobials can contribute to the development and spread of antimicrobial resistance, posing risks to patient safety.

The proposed amendment seeks to bring antimicrobials within the regulatory framework applicable to new drugs under the New Drugs and Clinical Trials Rules, 2019. Accordingly, manufacturers would be required to obtain permission from the Central Licensing Authority (CLA) before applying for a manufacturing licence from the concerned State Licensing Authority (SLA). This is expected to strengthen central regulatory oversight and help ensure the quality, safety and efficacy of antimicrobial products.

The draft notification has been issued to invite objections and suggestions from stakeholders and members of the public before the proposed amendment is considered for finalisation by the Central Government. Objections and suggestions, if any, may be submitted to the Under Secretary (Drugs), Ministry of Health and Family Welfare, Government of India, U-6, Work Hall–C Wing, First Floor, Kartavya Bhawan-1, New Delhi–110001, or through email at drugsdiv-mohfwatgovdotin, within 30 days from the date on which copies of the Gazette containing the draft rules are made available to the public.

PREV

Stay updated with the Breaking News Today and Latest News from across India and around the world. Get real-time updates, in-depth analysis, and comprehensive coverage of India News, World News, Indian Defence News, Kerala News, and Karnataka News. From politics to current affairs, follow every major story as it unfolds. IMD cities weather forecastsRain Cyclone Asianet News Official App

Read more

Recommended Stories

BJP Criticizes Rahul Gandhi Over Remarks on Indian Democracy in USA
Fugitive Raghesh Unnikochan Deported from UAE to India via INTERPOL